Haemonetics is trading at $96.06 (+6.41%) after no clearly identifiable company-specific announcement on August 18, 2026.
- The latest major catalyst was the August 6 fiscal first-quarter earnings release, now stale for this pre-market move.
- The release reported $339.4 million in revenue and $1.14 adjusted EPS.
- Recent analyst target increases, including BofA’s $100 target, may support sentiment, though no source directly links them to the overnight jump.